Blog
About

10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder following lung transplantation is more commonly of host origin.

      Archives of pathology & laboratory medicine

      Viral Matrix Proteins, metabolism, DNA, Viral, analysis, Epstein-Barr Virus Infections, complications, pathology, genetics, Female, Fluorescent Antibody Technique, Indirect, Herpesvirus 4, Human, isolation & purification, Humans, Immunocompromised Host, Lung Transplantation, adverse effects, Lymphoproliferative Disorders, etiology, Male, Middle Aged, Polymorphism, Restriction Fragment Length, Postoperative Complications, Tissue Donors, Aged, Cytochrome P-450 CYP2D6

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Posttransplantation lymphoproliferative disorder (PTLD) in patients who have undergone solid organ transplantation is thought to be mostly of host (ie, transplant recipient) origin, as opposed to being predominantly of donor origin, which is observed in patients who have undergone bone marrow transplantation. Donor-origin PTLDs reportedly follow a more indolent course than host-origin PTLDs. To determine the origin of PTLD and its clinical implications in patients who have undergone lung transplantation. Patients' medical records were reviewed for clinical data. We performed a molecular study to determine the origin of abnormal lymphoid cells in 4 PTLD cases identified from our autopsy files. Each case underwent restriction fragment length polymorphism analysis using polymerase chain reaction-based genotyping for CYP2D6. Epstein-Barr virus (latent membrane protein 1) immunostaining and polymerase chain reaction analysis were performed on PTLD-involved tissues. Three of 4 PTLD cases were of host origin, and the remaining case was of donor origin. Epstein-Barr virus was detected by immunohistochemical and polymerase chain reaction methods in all PTLD-involved tissues that were examined. There was no apparent difference in clinical manifestations between host-origin and donor-origin PTLD cases in our study. The PTLDs in our patients who had undergone lung transplantation were Epstein-Barr virus-positive and mostly of host origin, without any notable clinical difference from donor-origin PTLD.

          Related collections

          Author and article information

          Journal
          10.1043/1543-2165(2006)130[176:EVPLDF]2.0.CO;2
          16454557

          Comments

          Comment on this article